- Home
- VMEO vs TECX Comparison
VMEO vs TECX Comparison
Compare VMEO & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- TECX
- Stock Information
- Founded
- VMEO 2004
- TECX 2019
- Country
- VMEO United States
- TECX United States
- Employees
- VMEO N/A
- TECX N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- TECX
- Sector
- VMEO Technology
- TECX
- Exchange
- VMEO Nasdaq
- TECX Nasdaq
- Market Cap
- VMEO 832.5M
- TECX 746.6M
- IPO Year
- VMEO N/A
- TECX 2018
- Fundamental
- Price
- VMEO $4.89
- TECX $16.55
- Analyst Decision
- VMEO Buy
- TECX Strong Buy
- Analyst Count
- VMEO 3
- TECX 5
- Target Price
- VMEO $8.67
- TECX $77.75
- AVG Volume (30 Days)
- VMEO 1.2M
- TECX 226.9K
- Earning Date
- VMEO 05-05-2025
- TECX 05-24-2025
- Dividend Yield
- VMEO N/A
- TECX N/A
- EPS Growth
- VMEO 19.88
- TECX N/A
- EPS
- VMEO 0.16
- TECX N/A
- Revenue
- VMEO $417,006,000.00
- TECX N/A
- Revenue This Year
- VMEO $4.16
- TECX N/A
- Revenue Next Year
- VMEO $6.76
- TECX N/A
- P/E Ratio
- VMEO $33.69
- TECX N/A
- Revenue Growth
- VMEO N/A
- TECX N/A
- 52 Week Low
- VMEO $3.43
- TECX $1.40
- 52 Week High
- VMEO $7.90
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- VMEO 29.44
- TECX 30.52
- Support Level
- VMEO $5.31
- TECX $16.51
- Resistance Level
- VMEO $5.34
- TECX $23.06
- Average True Range (ATR)
- VMEO 0.16
- TECX 1.87
- MACD
- VMEO -0.02
- TECX 0.03
- Stochastic Oscillator
- VMEO 7.65
- TECX 4.79
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.